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Simultaneously characterizing the
comparative economics of routine female
adolescent nonavalent human
papillomavirus (HPV) vaccination and
assortativity of sexual mixing in Hong Kong
Chinese: a modeling analysis
Horace C. W. Choi1,2,3†, Mark Jit1,4,5, Gabriel M. Leung1, Kwok-Leung Tsui2 and Joseph T. Wu1*†
Abstract
Background: Although routine vaccination of females before sexual debut against human papillomavirus (HPV) has
been found to be cost-effective around the world, its cost-benefit has rarely been examined. We evaluate both the cost-
effectiveness and cost-benefit of routine female adolescent nonavalent HPV vaccination in Hong Kong to guide its policy,
and by extension that of mainland China, on HPV vaccination. One major obstacle is the lack of data on assortativity of
sexual mixing. Such difficulty could be overcome by inferring sexual mixing parameters from HPV epidemiologic data.
Methods: We use an age-structured transmission model coupled with stochastic individual-based simulations to estimate
the health and economic impact of routine nonavalent HPV vaccination for girls at age 12 on cervical cancer burden
and consider vaccine uptake at 25%, 50%, and 75% with at least 20 years of vaccine protection. Bayesian inference was
employed to parameterize the model using local data on HPV prevalence and cervical cancer incidence. We use the
human capital approach in the cost-benefit analysis (CBA) and GDP per capita as the indicative willingness-to-pay
threshold in the cost-effectiveness analysis (CEA). Finally, we estimate the threshold vaccine cost (TVC), which is the
maximum cost for fully vaccinating one girl at which routine female adolescent nonavalent HPV vaccination is cost-
beneficial or cost-effective.
Results: As vaccine uptake increased, TVC decreased (i.e., economically more stringent) in the CBA but increased in the
CEA. When vaccine uptake was 75% and the vaccine provided only 20 years of protection, the TVC was US$444
($373–506) and $689 ($646–734) in the CBA and CEA, respectively, increasing by approximately 2–4% if vaccine
protection was assumed lifelong. TVC is likely to be far higher when non-cervical diseases are included. The
inferred sexual mixing parameters suggest that sexual mixing in Hong Kong is highly assortative by both age and
sexual activity level.
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Conclusions: Routine HPV vaccination of 12-year-old females is highly likely to be cost-beneficial and cost-
effective in Hong Kong. Inference of sexual mixing parameters from epidemiologic data of prevalent sexually
transmitted diseases (i.e., HPV, chlamydia, etc.) is a potentially fruitful but largely untapped methodology for
understanding sexual behaviors in the population.
Keywords: Human papillomavirus, Vaccination, Cervical cancer, Hong Kong, Cost-benefit analysis, Cost-effectiveness
analysis, Mathematical model, Sexual mixing
Background
The cost-effectiveness of routine female adolescent human
papillomavirus (HPV) vaccination and other strategies
(e.g., vaccinating males as well) has been extensively stud-
ied for many high-income countries (e.g., the UK,
Australia, Canada) as well as middle- and low-income
countries (e.g., Malaysia, Brazil, Peru) [1]. The consensus
among these studies is that routine female adolescent
HPV vaccination is cost-effective. In contrast, very few
studies have examined the corresponding cost-benefit,
which is an important alternative criterion for health
technology assessment because (1) in some jurisdictions,
such as Hong Kong, health policymaking is based on
cost-benefit instead of cost-effectiveness; (2) economists
have suggested that cost-benefit analysis (CBA) is able to
capture a wider range of the benefits of vaccination com-
pared to cost-effectiveness analysis (CEA) [2]; and (3)
CBA and CEA may lead to discordant conclusions regard-
ing the economic favorability of health interventions due
to different but equally sound methodologies and assump-
tions [3].
Despite the recent advent of a second-generation HPV
vaccine (which targets nine HPV types that account for
approximately 90% of cervical cancer worldwide [4]),
Hong Kong and mainland China have not yet decided
whether to include HPV vaccines in their routine
immunization programs. The primary objective of this
study is to provide a robust evidence base for HPV
vaccination policy in the sentinel Chinese population of
Hong Kong by performing both CBA and CEA of rou-
tine female adolescent nonavalent HPV vaccination for
reducing cervical cancer burden using methodology that
conforms with health technology assessments in this
city. The health technology assessments framework for
HPV vaccination in Hong Kong can serve as a reference
for mainland China’s public health policy on prevention
of cervical cancer, which is the second-most common
cancer in women aged below 45 in the country [5].
A key challenge in a rigorous evaluation of HPV vac-
cination programs is to adequately parameterize the
HPV transmission model. To robustly evaluate the
health impact of HPV vaccination, evidence-based HPV
transmission models are needed to estimate the herd im-
munity effect [6]. Extensive research in recent years has
identified assortativity of sexual mixing and the duration
of naturally acquired immunity as two major sources of
uncertainty in our understanding of HPV transmission
dynamics [7–9]. Regarding sexual mixing, models for
heterosexual transmission of HPV require specification
on (1) heterogeneity in sexual activity levels (e.g., the
number of sexual partners over the past year) within
each age group and (2) assortativity of sexual mixing by
age and sexual activity level (i.e., how differences in age
and sexual activity level between two individuals affect
their probability of forming a sexual partnership). Most
populations, including Hong Kong, lack empirical data
on point (2), in which case assortativity of sexual mixing
is modeled by either extrapolating from the few popula-
tions with such data (e.g., a study for Austria used the
sexual mixing data from the UK [10]) or by making
hypothetical assumptions (e.g., [11]). Regarding natural
immunity, although a recent meta-analysis suggested
that natural recovery from HPV infection provides
modest short-term protection against re-infection
among females [9], the longevity of this effect remains
unknown. To account for the uncertainty in assortativity
of sexual mixing and natural immunity, we adopt the
novel approach of Korostil et al. [8], who suggested that
the underlying parameters could be inferred from HPV
epidemiologic data during model parameterization.
Consequently, as we evaluate the cost-benefit and cost-
effectiveness of routine female adolescent nonavalent
HPV vaccination for Hong Kong, we will also be simul-
taneously characterizing the underlying assortativity of
heterosexual mixing, which in itself is an important
knowledge gap on sexually transmitted infections.
Methods
Herein, we briefly describe the model structure. Please
see the Additional file 1 for more details on the model.
Model overview
Our model comprises (1) a deterministic age-structured
compartmental dynamic model for simulating heterosex-
ual transmission of high-risk HPV (HR-HPV) and (2) a
stochastic individual-based cohort model for simulating
the development of cervical cancer over the lifetime of
each female. This hybrid approach has been used in
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previous studies of HPV vaccination (e.g., [11]). We group
HR-HPV into four classes: (1) HPV-16; (2) HPV-18; (3)
HPV-OV (for ‘other vaccine types’), which comprises the
other five HR-HPV targeted by the nonavalent vaccine,
namely HPV-31, 33, 45, 52, and 58; and (4) HPV-NV,
which comprises all the non-vaccine HR-HPV. The dy-
namic model is used to estimate the model parameters
and the herd immunity effect after routine female adoles-
cent HPV vaccination has begun. The age-specific force of
infection from the dynamic model is fed into the stochas-
tic individual-based model to simulate cervical cancer
incidence for each birth cohort. The cohort model expli-
citly simulates cervical screening, which cannot be accur-
ately and easily performed with compartmental models
because of the history-dependent nature of screening and
treatment per the guidelines issued by the Hong Kong
College of Obstetricians and Gynecologists [12]. The time
step is 1 month in all simulations. The maximum age is
85 years for all individuals.
Natural history
Each individual enters the model at age 10 without any
HPV infection (Additional file 1: Figure S1). After a
female has been infected, she remains free of lesions for
some time and then either clears the infection or
progresses to cervical intraepithelial neoplasia (CIN1, 2,
or 3). We assume that individuals with CIN3 do not
recover naturally and will eventually progress to cervical
cancer if untreated. The mean duration of natural
immunity for HPV-16 and HPV-18 from HPV epidemio-
logic data are inferred during model parameterization
(see below). HPV-OV and HPV-NV each comprise
multiple HR-HPV that are unlikely to have significant
cross-immunity [13]. As such, we assume no natural im-
munity for HPV-NV (i.e., individuals remain fully
susceptible after clearance of infection). In contrast, to
avoid overestimating the herd immunity effect conferred
by vaccination [8], we allow natural immunity for
HPV-OV and infer its mean duration during model
parameterization. We assume that natural immunity
provides 100% protection against reinfection of the same
HPV class and that its duration is exponentially distrib-
uted. We model co-infections among the four HPV
classes by assuming that disease progression of a given
co-infection follows the progression rate of the most ag-
gressive class therein, whereas class-specific clearance is
unaffected by co-infections. We assume that the
duration of HPV infection is the same among males and
females [11]. When estimating the health burden associ-
ated with HPV, we consider only cervical cancer because
Hong Kong does not have robust age-specific data on in-
cidence of genital warts (more than 90% of which are
caused by HPV-6 and HPV-11, against which the nona-
valent vaccine is more than 90% efficacious) and other
forms of HPV-associated cancers (e.g., vulvar, penile). As
such, our study will tend to underestimate the health
and economic benefits of nonavalent HPV vaccination.
Sexual mixing
We stratify the population into two sexes (g ∈ {f,m}), 76
1-year age groups (a = 10,11,12,…,85), and three sexual
activity levels (s ∈ {none, low, high} that denote no, one,
and multiple sexual partners during the past 6 months,
respectively). Let Ng, a, u(t) be the number of individuals
in stratum (g, a, u) at time t, and cg, a, u be the rate at
which these individuals form new sexual partnerships.
The age-specific distribution of individuals with different
sexual activity levels are based on the sexuality study re-
sults published by the Family Planning Association of
Hong Kong (FPAHK) [14]; see Additional file 1 for de-
tails. We model assortativity of sexual mixing by age and
sexual activity based on the formulation in Walker et al.
[15]. Specifically, given that an individual in stratum (g,
a, u) forms a sexual partnership at time t, the probability
that their partner belongs to stratum (g', b, v), g ≠ g', is
ρg;a;u;b;vðtÞ ¼ εAεSΦ
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where δuv has value 1 when u = v and 0 otherwise, and
Φ(⋅) is the Gaussian kernel. We use the Gaussian kernel
to model age assortativity because its shape conforms
with intuition as well as the patterns empirically ob-
served in sexual activity surveys from the UK, Australia,
and the US [16–18]. In this formulation, age assortativity
is controlled by εA and σg whereas risk assortativity is
controlled by εS. For simplicity, we assume that σg is the
same for males and females.
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Let Ig, a, u, h(t) be the prevalence of HPV class h among
individuals in stratum (g, a, u) at time t. The force of
infection from HPV class h for individuals in stratum
(g, a, u) at time t is
λg;a;u;hðtÞ ¼
X
b
X
v
"
αaαbβhc

g;a;u;b;vðtÞρg;a;u;b;vðtÞ
Ig 0;b;v;hðtÞ
Ng 0;b;vðtÞ
#
where βh is the class-specific baseline probability of
transmission per sexual partnership, cg;a;u;b;vðtÞ is the ad-
justed contact rate between stratum (g, a, u) and (g', b, v)
(see Additional file 1 for details), and
αa ¼
1
1þ μ−1
W 2−W 1
a−W 1ð Þ
μ
if a < W 1
if W 1≤a≤W 2
if a > W 2
8<
:
for modeling the effect of age on susceptibility and infec-
tiousness (e.g., to reflect the age dependence of condom
use, which increased from 26% in the 15–19 age group
to 70% in the 18–27 age group according to the Youth
Sexuality Study 2011 by the FPAHK [19]). The model
assumes that susceptibility and infectiousness is (1)
highest (αa = 1) for individuals aged below W1; (2)
linearly decreases from 1 to μ as individuals age from
W1 to W2; and (3) remains at αa = μ for individuals aged
above W2. The parameters μ, W1, and W2 are inferred
during model parameterization.
Model parameterization
The following epidemiologic data were used to parameterize
the model:
1. Age-specific prevalence of HR-HPV in Hong Kong
as reported in two previous studies [20, 21].
2. Age-specific cervical cancer incidence in 1980–1984
as recorded by the Hong Kong Cancer Registry
[22]. We choose this period to minimize the
confounding effect of screening on cervical cancer
incidence (there are no data on screening coverage
in Hong Kong before 2000).
3. HR-HPV distribution among cervical cancer cases
in Hong Kong hospitals during 1972–1973 and
1984–1986 [23].
4. The cumulative proportion of cases with disease
progression and recovery for different stages of
HPV infection from two overseas studies [24, 25].
Analogous data are not available in Hong Kong.
We infer the following model parameters by fitting the
model to these data using Markov chain Monte Carlo
methods with non-informative flat priors [7]: (1)
class-specific progression and clearance rates for differ-
ent stages of HPV infection; (2) the mean duration of
natural immunity for HPV-16, HPV-18, and HPV-OV;
(3) baseline class-specific transmission probability per
sexual partnership (βh); (4) assortativity of sexual mixing
(εA, σg, and εS); and (5) age-specific susceptibility and in-
fectiousness (μ, W1, and W2).
Routine HPV vaccination
We compare routine vaccination for girls at age 12 to
opportunistic vaccination with status quo vaccine uptake
(12% [26]). We assume that the nonavalent HPV vaccines
are used in both routine HPV vaccination and status quo
opportunistic vaccination and that full vaccination is pro-
vided by the two-dose regime recommended for individ-
uals aged 9–14 years in Hong Kong [27]. Our previous
survey suggested that approximately 40–50% of mothers
in Hong Kong would consent to HPV vaccination for their
adolescent daughters [28]. On the other hand, the uptake
in the UK and Australia is 70–80%, which is the highest
around the world [29, 30]. As such, we consider three sce-
narios of vaccine uptake for routine vaccination, namely
25%, 50%, and 75%. The class-specific vaccine efficacy is
as follows [4, 31]: (1) 95.5% (95% confidence interval
90.0%–98.4%) for HPV-16; (2) 95.8% (84.1%–99.5%) for
HPV-18; (3) 96.0% (94.4%–97.2%) for HPV-OV; and (4)
0% for HPV-NV. The latest clinical trial results showed
that individuals who were vaccinated at age 9–15 years
while they were still sexually naive remained seropositive
(against vaccine-type HPV) after 10 years [32]. A model-
ing study used immunogenicity data to estimate that vac-
cine protection will likely persist for at least 20 years [33].
As such, we consider three possibilities, namely 20-year,
30-year, and lifelong protection.
Cervical cancer screening
We assume that vaccination does not affect screening
behavior. The Cervical Screening Programme (CSP) in
Hong Kong recommends women aged between 25 and
65 years to follow the 1-, 1-, 3-yearly cycle of cervical
screening (i.e., screening annually for their first 2 years
of screening and then triennially if their screening
results remain negative) [27]. Based on the screening up-
take data from the Behavioral Risk Factor Surveillance
System surveys [27] and published literature [34, 35], we
assume that screening uptake increased linearly from
40% in 1980 to 70% in 2004 when CSP was launched
and remained at 70% thereafter. We assume that the
sensitivity of cervical cytology at the threshold of
atypical squamous cells of undetermined significance in
detecting CIN2/3 and cervical cancer are 80% and 100%,
respectively [36] (see Additional file 1 for details).
CBA and CEA
In the CBA, we used the human capital approach to
monetize health and life-year loss into productivity
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loss based on average personal income [37] (see
Additional file 1 for details). In the CEA, we set the
willingness-to-pay threshold for the incremental cost-ef-
fectiveness ratio (defined as the additional cost per each
quality-adjusted life-year gained when comparing two in-
terventions) at one local gross domestic product (GDP)
per capita which is the lowest threshold used in cost-ef-
fectiveness studies of vaccination programs for Hong
Kong [38]. The average GDP per capita in Hong Kong
during 2012–2016 was US$40,099 [39]. To assess the
long-term impact of HPV vaccination, we estimated the
changes in costs and health across the lifetimes of all fe-
male cohorts over a time horizon of 100 years. For ex-
ample, at year 99, the incoming cohort will incur costs
and benefits over its lifetime. The costs of screening and
treatments were based on (1) charges for private patients
in public hospitals, which account for over 90% of in-
patient care in Hong Kong [40], and (2) expert opinions
among local oncologists and gynecologists. Health utility
parameters were based on overseas studies due to the lack
of local data [41, 42]. Following the WHO guidelines, we
discounted cost and health utility for women regardless of
their ages after year 1 at 3% per annum [43]; the first age
that discounting began was age 10 years. All cost figures
were denominated in US dollars.
Cost of vaccination
We set the vaccine cost in the status quo scenario at
US$284 based on the price list in the FPAHK (which is a
non-profit organization) [14] and the two-dose regime
as recommended for individuals aged 9–14 years in
Hong Kong [27]. Instead of explicitly modeling vaccine
dose schedules and costs for routine HPV vaccination,
we considered the cost required to fully vaccinate one
girl (which includes the procurement, logistical, and
administrative costs) as the outcome of our CBA and
CEA. With this approach, we performed a head-to-head
comparison between the CBA and CEA threshold
vaccine cost, which was defined as the highest cost of vac-
cination at which the routine HPV vaccination program is
cost-beneficial (i.e., the net monetary benefit is positive)
and cost-effective (i.e., the incremental cost-effectiveness
ratio is below the willingness-to-pay threshold), respect-
ively. We denoted the CBA and CEA threshold vaccine
cost by TVCCBA and TVCCEA, respectively.
Probabilistic sensitivity analysis
For each vaccination uptake and protection scenario, we
considered 10,000 probabilistic sensitivity analysis sce-
narios which comprise all combinations of (i) 100 sets of
transmission and natural history parameters randomly
generated from their posterior distributions obtained
from model parameterization (Additional file 1: Table
S2); and (ii) 100 sets of vaccine efficacy, screening, cost,
and health utility parameters randomly generated from
their plausible ranges shown in Additional file 1: Tables
S3–S5 [4, 41, 42].
Results
Transmissibility and duration of natural immunity
The fitted model was largely congruent with the epide-
miologic data used for model parameterization (Fig. 1).
The baseline probability of transmission per partnership
was 0.75 (95% credible interval 0.50–0.96), 0.88 (0.60–
0.98), 0.93 (0.80–0.99), and 0.61 (0.50–0.71) for HPV-16,
HPV-18, HPV-OV, and HPV-NV, respectively (Fig. 2a).
The mean duration of natural immunity was 16 (3–83),
17 (4–75), and 0.7 (0.5–1.7) years for HPV-16, HPV-18,
and HPV-OV, respectively (Fig. 2b). The inferred
ephemeralness of natural immunity for HPV-OV was
consistent with its multi-type nature (i.e., clearance of
one type of HPV-OV will unlikely prevent infection by
other types of HPV-OV). As individuals reach age 21
(16–24), their susceptibility and infectiousness began to
fall gradually until they reached age 24 (21–27) (Fig. 2c).
The total decrease in susceptibility and infectiousness
over this period was 53% (47%–59%).
Assortativity of sexual mixing
Sexual mixing was highly assortative by both age (εA =
0.77 (0.29 – 0.99); σg = 2.1 (0.2 – 0.49)) and sexual activity
level (εS = 0.98 (0.89 – 0.99)) (Fig. 2d, e). The inferred
level of age assortativity in sexual mixing was compar-
able with that empirically observed in sexual surveys
from the UK [44] and Australia [17]. In our fitted model,
74% (43%–97%) and 84% (60%–99%) of adult heterosex-
ual partnerships had less than 5 and 10 years of age dif-
ference between the two partners, respectively.
Epidemiologic impact of routine female adolescent HPV
vaccination
The prevalence of HPV-16, HPV-18, and HPV-OV de-
crease monotonically over time and reached a steady state
50–60 years after routine female vaccination began
(Fig. 3a). This agrees with intuition because, in order for
the routine vaccination program to confer maximal
population-level benefit, all sexually active women in the
population must have had the opportunity to receive the
vaccine at age 12. Unsurprisingly, the prevalence of
HPV-NV was constant over time because the nonavalent
vaccine provides no protection against these HR-HPV
types. Vaccine-type HR-HPV prevalence decreased with
vaccine uptake as the latter increased from 10% to 90%
with weak decreasing marginal return (Fig. 3b). Vaccine-
type HR-HPV would have been eliminated if vaccine pro-
tection lasted for more than 30 years and routine vaccine
uptake was higher than 90%. This result is consistent with
the recent review of herd immunity threshold for HPV
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vaccination [6, 45]. The decrease in age-standardized inci-
dence of cervical cancer during the first 20 years is not
caused by vaccination but instead attributed to increased
screening uptake in Hong Kong since CSP was launched
in 2004 (Fig. 3c; see Additional file 1 for details of cervical
screening in Hong Kong). Because HPV infections take at
Fig. 1 Comparison of the empirical data and the fitted model. a Age-specific HPV prevalence. b Age-specific incidence of cervical cancer.
c Distribution of HPV types in cervical cancer lesions. d–f Cumulative proportions of disease progression and clearance within 2 years for HPV
infections without lesions, CIN1 and CIN2. Error bars indicate the 95% credible intervals for the fitted model and 95% confidence intervals for the data
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least 20 years to progress into malignancy in most cases of
cervical cancer, the differential impact of vaccine uptake
between status quo and routine vaccination on cervical
cancer incidence would not be apparent until 20 years
after routine vaccination had begun. Population-level
benefit of routine vaccination on cancer incidence reached
steady state 70–80 years after routine vaccination began.
Compared to status quo opportunistic vaccination, routine
vaccination with 25%, 50%, and 75% uptake further re-
duced the age-standardized cervical cancer incidence in
year 100 by 21%, 57%, and 85%, respectively, with lifelong
vaccine-induced protection, and by 19%, 51%, and 78%, re-
spectively, with 20-year protection.
Comparative threshold vaccine costs (TVC) between CBA
and CEA
As expected, the TVC decreased (i.e., became economic-
ally more stringent) as the duration of vaccine protection
decreased (Fig. 4a). As vaccine uptake increased, TVCCBA
decreased but TVCCEA increased with TVCCBA > TVCCEA
across all scenarios considered: TVCCBA was lower than
TVCCEA by approximately 13%, 30%, and 36% when vac-
cine uptake was 25%, 50%, and 75%, respectively (Fig. 4a).
When the vaccine provided only 20 years of protection
and vaccine uptake was 75% (i.e., the scenario under
which TVCCBA was the lowest), the total cost for fully vac-
cinating one girl would need to be less than US$444
($373–506) and $689 ($646–734) for routine HPV vaccin-
ation to be cost-beneficial and cost-effective, respectively.
Compared to this scenario, TVCCBA (TVCCEA) increased
by 2.3% (3.9%) if vaccine protection duration increased to
30 years or longer. If vaccine uptake decreased from 75%
to 50%, TVCCBA increased by 6.6% whereas TVCCEA de-
creased by 2.3%. For TVCCBA and TVCCEA to be similar,
the willingness-to-pay threshold would need to be ap-
proximately US$30,000 for vaccine uptake at 25% and
US$20,000 for vaccine uptake at 75% (Fig. 4b).
Discussion
Main conclusions and their implications
We have evaluated the cost-benefit and cost-effective-
ness of routine female adolescent nonavalent HPV vac-
cination for reducing cervical cancer burden in Hong
Kong. Our results suggest that, at a vaccine uptake of
between 25% and 75%, routine vaccination for
12-year-old girls (i.e., regardless of their sexual activity
characteristics) as part of a centrally funded program
represents good value for money if the cost of fully
vaccinating one girl is no greater than US$444 ($373–
506) and $689 ($646–734), respectively. The current
market price of fully vaccinating one girl at age 12 at the
FPAHK (as of November 2017) is $284, and the tender
prices for bulk purchases in Italy, Norway, South Africa,
and Spain were 66–77% lower than market prices [46].
Thus, we believe that the tender price of a centrally pro-
cured HPV vaccine in Hong Kong is likely to be well
below the lower limit of our most conservative TVC es-
timate ($373) and thus provide the basis for a routine fe-
male adolescent HPV vaccination program that is both
cost-beneficial and cost-effective.
Furthermore, because of the lack of local data, our
analysis did not examine many of the benefits of HPV
vaccination such as protection against anogenital warts,
recurrent respiratory papillomatoses, or vulvar, vaginal,
penile, anal, and oropharyngeal cancers. The value of
protection against these non-cervical cancers has been
estimated to be almost as great as the value of protecting
against cervical cancers in some scenarios [47]. Further,
our CBA is based on human capital calculations, valuing
health in terms of a woman’s productive capacity, and
does not capture the additional value that people put on
averting suffering due to disease. If these considerations
Fig. 2 Key parameter estimates in the fitted model. Circles and vertical
lines indicate posterior medians and 95% credible intervals. a Baseline
probability of HPV transmission per sexual partnership. b Mean duration
of natural immunity (on log-scale). c Age-specific susceptibility and
infectiousness. The line and shades indicate medians and 95% credible
intervals. d εA and εS for assortativity of sexual mixing. e Joint posterior
distribution of εA and σg. Higher values of εA and smaller values of σg
mean higher degree of age assortativity. Darker color indicates higher
density. See Additional file 1: Table S2 for all inferred parameter values
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Fig. 3 (See legend on next page.)
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are taken into account, then the TVC for the CBA is
likely to be even greater than that for the CEA. There-
fore, it is almost certain that centrally funded routine
HPV vaccination for 12-year-old girls will be both
cost-beneficial and cost-effective in Hong Kong.
To our knowledge, our study is the first to compare the
CBA and CEA implications of HPV vaccination. For Hong
Kong, the CBA threshold vaccine cost is always lower (i.e.,
economically more stringent) than its CEA counterpart,
i.e., TVCCBA/TVCCEA < 1. The generalizability of this find-
ing to other populations hinges on two other factors. The
first factor is that CBAs in Hong Kong consider only
changes in economic productivity (and not individual
willingness-to-pay to avoid premature death as in the US
or UK). Intuitively, TVCCBA/TVCCEA increases with the
ratio of average personal income to willingness-to-pay
threshold. The second factor is the age distribution of cer-
vical cancer in relation to retirement age and life expect-
ancy. HPV vaccination will be (1) more cost-beneficial if
the gap between the average age of cervical cancer cases
and retirement age increases; and (2) more cost-effective
if the gap between the average age of cervical cancer and
life expectancy increases. Consider an illustrative compari-
son among Hong Kong, the US (with one GDP per capita
as the willingness-to-pay threshold, i.e., approximately
$58,000), and the UK (with £20,000–30,000 as the
willingness-to-pay threshold). The ratio of average per-
sonal income to willingness-to-pay threshold is approxi-
mately 0.5 for Hong Kong, 0.72 for the US, and > 0.7 for
the UK. On the other hand, the median age of cervical
(See figure on previous page.)
Fig. 3 Epidemiologic impact of routine female adolescent HPV vaccination. The curves and shades indicate the medians and 95% central ranges
of the outcomes across all 100 probabilistic sensitivity analysis scenarios on natural history parameters, respectively. a Age-standardized HPV
prevalence over time. b Age-standardized HPV prevalence after 100 years of routine vaccination as a function of vaccine uptake. c Age-standardized
incidence of cervical cancer over time
Fig. 4 Comparative threshold vaccine cost between cost-benefit analysis and cost-effectiveness analysis. The curves and shades indicate the
medians and 95% central ranges of the outcomes, respectively, across all 10,000 probabilistic sensitivity analysis combinations of natural history
and health economic parameter values. The outcomes at 25%, 50%, and 75% vaccine uptake are used to estimate the outcomes at other vaccine
uptake levels using linear interpolation. a Threshold vaccine cost, i.e., the maximum cost for vaccination at which routine vaccination of girls at
age 12 is cost-beneficial (TVCCBA) and cost-effective (TVCCEA) compared to status quo vaccine uptake (12%) at the current market price (US$284
for the two-dose schedule). b The willingness-to-pay threshold at which TVCCBA = TVCCEA. The GDP per capita in Hong Kong is US$40,099
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cancer diagnosis is 45 in the UK, 49 in the US, and 52 in
Hong Kong, whereas the female life expectancy is 82, 79,
and 87, respectively. The retirement age in these popula-
tions are similar. Applying the rationale above, the differ-
ence between TVCCBA and TVCCEA is likely to be
significantly smaller for the US and UK compared to
Hong Kong, and thus CBA and CEA will likely result in
similar conclusions on the health economics of HPV vac-
cination in the US and UK.
Comparison to other studies
A recently published review of cost-effectiveness studies
of HPV vaccination [48], together with a more updated lit-
erature search, generated seven CEAs of nonavalent HPV
vaccination in high-income countries [10, 49–54] and two
for low- and middle-income countries [55, 56]. Most of
these studies focused on switching from the use of either
the bivalent or quadrivalent vaccines to nonavalent vac-
cine in existing vaccination programs [10, 49, 50, 52–54],
while one study examined providing additional nonavalent
vaccines to females who have already received three doses
of quadrivalent vaccine [51]. Thus, they all differed from
our study, which focused on comparing a scenario of an
organized program using nonavalent vaccination at high
coverage to an existing opportunistic program also using
nonavalent vaccination.
Despite the different model scenarios, some results
from previous studies can be compared with ours. We
estimate that the female-only organized HPV vaccination
with 75% vaccine uptake and lifelong vaccine protection
would reduce cervical cancer incidence by 85% com-
pared to 12% opportunistic vaccine uptake. In the CEAs
for high-income countries, the additional reduction in
cervical cancer for routine vaccination compared to no
vaccination (which is the most similar scenario to the
opportunistic vaccination scenario in our study) ranged
between 70% and 92%, depending on vaccine uptake of
females and males [10, 49, 50, 52, 54].
Although not explicitly stated, the TVC of nonavalent
HPV vaccines for routine vaccination compared to no vac-
cination can be estimated from two previous studies
where sufficient detail about the overall cost of vaccin-
ation is reported [52, 53]. In the Canadian CEA [53], the
derived TVC for vaccination of 12-year-old females with a
three-dose nonavalent vaccine schedule (as considered in
the study) compared to no vaccination was estimated to
be US$798. The estimation was based on a
willingness-to-pay threshold of US$38,000 (CAD$40,000)
per QALY gained, with a healthcare payer perspective,
80% female vaccination coverage, and 20-year duration of
vaccine-induced protection. In another CEA for vaccinat-
ing both sexes in the US with a three-dose nonavalent vac-
cine schedule [52], the estimated TVC was US$959, using
a willingness-to-pay threshold of US$50,000, a societal
perspective, lifelong vaccine protection, and vaccine
uptake of 46% and 29% among females and males aged
13–17 years, respectively. Given current opportunistic
vaccine uptake of 12% [26] and assuming that the nonava-
lent vaccine is used for both organized and opportunistic
vaccination, our study estimates that the TVC for
organized female vaccination is US$689 at a willingness-
to-pay threshold of US$40,099 per QALY gain, societal
perspective, two-dose regimen, 75% vaccine coverage, and
20-year duration of vaccine-induced protection. The
slightly lower TVC in our study is probably because (1)
we did not consider non-cervical diseases in our study; (2)
the opportunistic program that we considered already
generates some herd protection so less benefit is expected
from an organized program; and (3) we assumed only
20-year duration of vaccine protection.
Strengths and limitations of the study
Our study has several other important limitations. First,
we assumed that the duration and transmissibility of
HPV infection are the same for males and females.
While some evidence from other settings suggests that
this is not generally true [9], Hong Kong does not have
the necessary data (e.g., HPV prevalence or seropreva-
lence among males) for us to account for such hetero-
geneity. Second, we have not considered potential
changes to cervical cancer screening (cytology is the
most common primary screening method) and coverage
after routine HPV vaccination begins. Depending on
vaccine uptake, screening guidelines may be updated ac-
cordingly to optimize the cost-effectiveness and/or
cost-benefit of screening [57]. Moreover, the use of pri-
mary HPV testing for cervical cancer screening will
likely improve the positive predictive value of screening
when the uptake of HPV vaccination is high [49]. Third,
for model parsimony, we have assumed that assortativity
in sexual mixing is the same for both sexes, which may
not be accurate. Fourth, the health utility parameters in
this study are based on studies from other settings that
may not accurately reflect the situation in Hong Kong.
Fifth, because there is no evidence on the societal
willingness-to-pay threshold for cervical cancer in Hong
Kong, we used one GDP per capita, which is the lowest
willingness-to-pay threshold used by all the vaccination
CEA studies in Hong Kong reviewed in Wong et al. [38].
The TVC from a CEA would be lower if the
willingness-to-pay threshold is lower than that assumed
here. Sixth, our CBA relies on valuing avoided morbidity
and mortality using human capital calculations. The
CBA threshold vaccine cost might be different if other
methods are used (e.g., friction cost method [58] or
approaches based on value of statistical life years [59]).
Finally, the validity of the inferred parameters is limited
by the data available for model parameterization and the
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associated assumptions imposed for fitting the model to
these data. For example, transitions between CIN grades
are based on data with 2-year follow-up periods and as-
sumed to be Markovian, which might be inaccurate (e.g.,
we assume that a lesion is equally likely to clear regard-
less of how long it has persisted within the same CIN1
or CIN2 grade).
A major strength of our study is that, as we evaluate
the health economics of HPV vaccination, we simultan-
eously characterize sexual mixing in Hong Kong by fit-
ting the transmission model to epidemiological data
[60]. The resulting parameter estimates suggest that sex-
ual mixing in Hong Kong is, as would be anticipated,
highly assortative by both age and sexual activity level.
The level of age assortativity inferred in our study is
comparable to that reported in sexual surveys from the
UK and Australia, which lends support to the validity of
our estimates. Given the substantial costs of sexual sur-
veys and the difficulty of eliciting truthful responses on
sexual behaviors, inference of sexual mixing parameters
from epidemiologic data of sexually transmitted diseases
(including HPV, chlamydia, etc.) is a potentially fruitful
but underused methodology for understanding sexual
behaviors in the population. Our study provides a first
step in this direction.
The Greater Bay Area (GBA) Initiative in the 13th
5-year plan (2016–2020) of China aims to link the cities
of Hong Kong, Macau, Guangzhou, Shenzhen, Zhuhai,
Foshan, Zhongshan, Dongguan, Huizhou, Jiangmen, and
Zhaoqing into an integrated economic, business, and
technology hub that constitutes an area of 56,000 km2, a
combined population of 68 million, and an economy of
$1.51 trillion. Given the low uptake of HPV vaccination
and cervical cancer screening and the high burden of
cervical cancer in these cities, prevention of cervical
cancer will likely be a top-priority public health issue in
the GBA Initiative. Over the next decade, demographics,
sexual mixing, and disease transmission in these hetero-
geneous cities will be substantially impacted by the
massive increase in short- and long-term human mobil-
ity and interaction brought about by the GBA Initiative.
A recent study showed that interstate migration has a
strong impact on the population-level benefit of HPV
vaccination in the US because of herd immunity and the
long duration between HPV infection and resultant
cervical cancer [61]. As such, the GBA cities will need to
coordinate their evaluations and policies to maximize
the benefit of their HPV vaccination programs. Our
study for Hong Kong provides a robust basis for the de-
velopment of such a cooperative framework.
Conclusions
Routine HPV vaccination of 12-year-old females is
highly likely to be cost-beneficial and cost-effective in
Hong Kong. Inference of sexual mixing parameters from
epidemiologic data of prevalent sexually transmitted dis-
eases (i.e., HPV, chlamydia, etc.) is a potentially fruitful
but largely untapped methodology for understanding
sexual behaviors in the population.
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